Maternal sirolimus therapy and fetal growth restriction
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
##plugins.themes.bootstrap3.article.details##
sirolimus, fetal growth restriction, mTOR
2. Gupta MB, Jansson T. Novel roles of mechanistic target of rapamycin signaling in regulating fetal growth. Biol Reprod 2019; 100(4):872–884.
3. Roos S, Jansson N, Palmberg I, Säljö K, Powell TL, Jansson T. Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth. J Physiol 2007; 582(1):449–459.
4. Dong J, Shin N, Chen S, Lei J, Burd I, Wang X. Is there a definite relationship between placental mTOR signaling and fetal growth? Biol Reprod 2020; 103(3):471–486.
5. Soblet J, Kangas J, Nätynki M, et al. Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) Mutations. J Invest Dermatol 2017; 137(1):207–216.
6. Terata M, Kikuchi A, Kanasugi T, Fukushima A, Sugiyama T. Association of blue rubber bleb nevus syndrome and placenta previa: Report of a case. J Clin Ultrasound 2013; 41(8):517–520.
7. Framarino-Dei-Malatesta M, Derme M, Napoli A, et al. Placental, lipid, and glucidic effects of mammalian target of rapamycin inhibitors: Impact on fetal growth and metabolic disorders during pregnancy after solid organ transplantation. Transplant Proc 2014; 46(7):2254–2258. http://dx.doi.org/10.1016/j.transproceed.2014.07.047.
8. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006; 82(12):1698–1702.
9. Armenti VT, Radomski JS, Moritz MJ, et al. Report from the national transplantation pregnancy registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2001:97-105. PMID: 12211807.
10. Shen L, Xu W, Gao J, et al. Pregnancy after the diagnosis of lymphangioleiomyomatosis (LAM). Orphanet J Rare Dis 2021; 16(1):1–7. https://doi.org/10.1186/s13023-021-01776-7.
11. Pluym ID, Sklansky M, Wu JY, et al. Fetal cardiac rhabdomyomas treated with maternal sirolimus. Prenat Diagn 2020; 40(3):358–364.
12. Barnes BT, Procaccini D, Crino J, et al. Maternal sirolimus therapy for fetal cardiac rhabdomyomas. N Engl J Med 2018; 378(19):1844-1845. doi: 10.1056/NEJMc1800352. PMID: 29742370; PMCID: PMC6201692.
13. Park H, Chang CS, Choi SJ, Oh S young, Roh CR. Sirolimus therapy for fetal cardiac rhabdomyoma in a pregnant woman with tuberous sclerosis. Obstet Gynecol Sci 2019; 62(4):280–284.
14. Chu S, Liu K, Chiang Y, Wang H, Lai P. Sirolimus Used During Pregnancy in a Living Related Renal Transplant Recipient : A Case Report. 2008; 2448(5):2446–2448.
15. Framarino Dei Malatesta M, Corona LE, et al. Successful pregnancy in a living-related kidney transplant recipient who received sirolimus throughout the whole gestation. Transplantation 2011; 91(9):69–71.
16. MacDonald AS, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22 Suppl B:B101-121. doi: 10.1016/s0149-2918(00)89027-x.
17. Barlow AD, Nicholson ML, Herbert TP. Evidence for rapamycin toxicity in pancreatic β-Cells and a review of the underlying molecular mechanisms. Diabetes 2013; 62(8):2674–2682.
18. Laribee RN. Transcriptional and Epigenetic Regulation by the Mechanistic Target of Rapamycin Complex 1 Pathway. J Mol Biol 2018; 430(24):4874–4890.
19. Elghazi L, Blandino-Rosano M, Alejandro E, Cras-Méneur C, Bernal-Mizrachi E. Role of nutrients and mTOR signaling in the regulation of pancreatic progenitors development. Mol Metab 2017; 6(6):560–573.
20. Robinson JF, Hamilton EG, Lam J, Chen H, Woodruff TJ. Differences in cytochrome p450 enzyme expression and activity in fetal and adult tissues. Placenta 2020; 100(10):35–44.
21. Hakkola J, Raunio H, Purkunen R, et al. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol Neonate 2001; 80(3):193–201.
22. Dai C, Walker JT, Shostak A, et al. Tacrolimus- And sirolimus-induced human β cell dysfunction is reversible and preventable. JCI Insight 2020; 5(1):e130770. https://doi.org/10.1172/jci.insight.130770.
23. Hakkola J, Pelkonen O, Fasanen M, Raunio H. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto- placental unit: Role in intrauterine toxicity. Crit Rev Toxicol 1998; 28(1):35–72.
24. OCallaghan JL, Clifton VL, Prentis P, Ewing A, Miller YD, Pelzer ES. Modulation of placental gene expression in small-for-gestational-age infants. Genes (Basel) 2020; 11(1):80. doi: 10.3390/genes11010080. PMID: 31936801; PMCID: PMC7017208.
25. Wang T, Tsui B, Kreisberg JF, et al. Epigenetic aging signatures in mice livers are slowed by dwarfism, calorie restriction and rapamycin treatment. Genome Biol 2017; 1–11.
26. Lazo-De-La-Vega-Monroy ML, Mata-Tapia KA, Garcia-Santillan JA, et al. Association of placental nutrient sensing pathways with birth weight. Reproduction 2020; 160(3):455–468.
27. Figueras F, Caradeux J, Crispi F, Eixarch E, Peguero A, Gratacos E. Diagnosis and surveillance of late-onset fetal growth restriction. Am J Obstet Gynecol 2018; 218(2S):S790-S802.e1. doi: 10.1016/j.ajog.2017.12.003.
28. Goto E. Prediction of low birthweight and small for gestational age from symphysis-fundal height mainly in developing countries: A meta-analysis. J Epidemiol Community Health 2013; 67(12):999–1005.
29. Chauhan SP, Beydoun H, Chang E, et al. Prenatal detection of fetal growth restriction in newborns classified as small for gestational age: correlates and risk of neonatal morbidity. Am J Perinatol 2014; 31(3):187–194.
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.